# Lucent AD Complete

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/lucent-ad-complete
Canonical HTML page: https://getyourbrief.com/entity/lucent-ad-complete

## Timeline

- **2026-03-02**: Earnings Call — Management confirms CMS reimbursement rate of $897 and 2025 assay expansion.
- **2026-03-02**: Q4 2025 Earnings — Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
- **2026-01-15**: FDA Submission — 510(k) premarket notification submitted for Lucent AD Complete.
- **2026-01-15**: FDA 510(k) Submission — Premarket notification submitted for Lucent AD Complete diagnostic test.
- **2025-12-31**: Q4 2025 Close — Quanterix reports $43.9M in revenue with 25% YoY growth.
- **2025-12-31**: CMS Reimbursement Milestone — CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
- **2025-01-01**: Assay Portfolio Expansion — Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.

## Recent coverage (3 stories, network-wide)

### Growth Divergence: On Holding and Sportradar Surge as Quanterix Pivots
2026-03-04 00:22:42 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 6

A wave of Q4 2025 earnings reports reveals a stark performance gap between high-margin consumer platforms and specialized technology firms. While On Holding and Sportradar delivered record margins and aggressive capital returns, Quanterix and BigBear.ai faced organic declines despite achieving critical regulatory and liquidity milestones.
Full story: https://getfinancebrief.com/story/growth-divergence-on-holding-sportradar-quanterix-earnings

### Quanterix Advances Alzheimer’s Strategy Amidst 25% Revenue Growth and FDA Filing
2026-03-04 00:21:33 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 6

Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
Full story: https://getbiobrief.com/story/quanterix-q4-2025-alzheimers-diagnostic-strategy-fda-filing

### Quanterix Secures CMS Reimbursement for Alzheimer’s Test Amid Q4 Growth
2026-03-04 00:20:22 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 6

Quanterix reported a 25% year-over-year revenue increase to $43.9 million in Q4 2025, driven by a surge in diagnostics partner revenue and critical regulatory milestones. The company achieved a commercial breakthrough with a $897 CMS reimbursement rate for its Lucent AD Complete test, positioning it for large-scale clinical adoption.
Full story: https://gethealthbrief.com/story/quanterix-q4-2025-alzheimers-diagnostics-milestone

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.